Success story of Aurobindo Pharma

In the period between 1988-89, the company only manufactured penicillin. They have since then expanded into antibiotics, anti-allergic, antiretrovirals, cardiovascular, central nervous system and gastroenterological categories.

In 2018, an Indian pharmacy became the second-largest generic pharmaceutical company in the world’s toughest market, the United States of America. We are talking about an Indian pharma company - Aurobindo Pharma. Not only did this company rival global giant Mylan it also gave severe competition to the world’s largest generic drug manufacturer -  Teva. Their marketing partners are AstraZeneca and Pfizer. The company’s founder. Ramprasad Reddy was one of the few drug manufactures that were invited to speak at the United Nations in 2006.

The journey of Aurobindo Pharma and its founder Ramprasad Reddy is truly inspiring. After his postgraduation in Commerce from Venkateshwara University, he along with friend Nityananda Reddy started trading. Nityananda Reddy with his education in Chemistry and work experience at Tini Pharma helped Ramprasad a lot. The small chemical traders soon turned their venture into a multinational pharmacy company worth billions of dollars. 

The company was founded in 1986 in Andra Pradesh. It was later converted into a Public Limited Company in 1992. In the period between 1988-89, the company only manufactured penicillin. They have since then expanded into antibiotics, anti-allergic, antiretrovirals, cardiovascular, central nervous system and gastroenterological categories. In 2014 for $41 million, Aurobindo purchased Actavis’s operation in seven European countries. In 2017, they acquired Portugal’s Generis for a whopping €135 million. They also acquired four biosimilar products from Swiss-based TL Biopharmaceuticals AG.

They are the largest manufacturer of Ampicillin and Cloxacillin in India. In 2018, 90% of the company’s revenue came from exports. Today, 70% of its revenue comes from exports that occur in 125 countries. Currently, an estimated 14% comes from generic injectables and oncology injectables. For the former Aurobindo has an estimated $400 million and for the latter $95 million. In FY21, generic injectables and the ophthalmic section alone reported Rs 9.3 billion in revenues. This was 5.9% of their overall revenue. 

Aurobindo Pharma and its founder Ramprasad Reddy’s tale is an inspiration to many. Coming from a humble background he has made for himself a fortune. Reddy, despite his language deficiencies, truly holds power in any negotiation. He has a steadfast decision making prowess and a discipline of keeping consistent prices. These traits have helped Reddy transform its small venture into a global giant in pharmaceuticals. 

Tags : #AurobindoPharma #RamprasadReddy #NityanandaReddy #AstraZeneca #Pfizer #multinationalpharmacy #pharmaceuticals #success #medicircle #smitakumar

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

10 PCOS Warning Signs That Need Your AttentionDecember 27, 2024
Experts Dub 2024 as the Year of Technologies and Innovations in Healthcare; Stress on further Integration of Technologies December 27, 2024
Aakash Healthcare Partners with Japan for Groundbreaking Surgical Intervention: A Global Collaboration to Revolutionize Cardiovascular CareDecember 26, 2024
Traditional Medicine Goes Global: How Ayush 2024 Reimagined WellnessDecember 26, 2024
Aster Guardians Global Nursing Award 2025 worth INR 2 Crore now open for nominations worldwide December 26, 2024
Holiday Season Round the Corner? 6 Daily Habits That Could Be The Reason Behind Your Fatty LiverDecember 26, 2024
Healing the Nation: Doctors as Architects of a Healthier FutureDecember 26, 2024
Brewing Health Benefits: Can Coffee and Tea Help Fight Head and Neck Cancers?December 26, 2024
Seven-Year-Old Fights Back Against Rare Autoimmune DiseaseDecember 26, 2024
Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive YearDecember 26, 2024
American Oncology Institute (AOI) in Nagpur Restores Mobility with KyphoplastyDecember 26, 2024
Sanjeevani Healthcare & Wellness Expo 2024: A Dynamic Platform for Global Healthcare CollaborationDecember 23, 2024
Ranitidine: Saviour or Suspect? The Truth Behind the Stomach Acid RemedyDecember 23, 2024
From One-Size-Fits-All to Precision Medicine: The New Hope for Rare Bone Cancer PatientsDecember 23, 2024
World Meditation Day: India’s Gift of Peace to a Chaotic WorldDecember 23, 2024
Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and TreatmentDecember 23, 2024
Black Angels remind us of centuries of injustices plaguing the TB responseDecember 20, 2024
Healthcare Startups to Watch Out for in 2025December 20, 2024
Biobank Blueprint: Redefining Diabetes Diagnosis and Treatment in IndiaDecember 20, 2024
The Future of Malaria Prevention: Can This Vaccine Eliminate the Disease?December 20, 2024